• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Empliciti, Revlimid combo falls short in multiple myeloma pharmatimes
    March 12, 2020
    Bristol-Myers Squibb has revealed that Empliciti (elotuzumab), when added to BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone, has not proved successful in extending the time patients with newly-diagnosed myeloma who were ineligible for ...
  • US approves new use for BMS’ Empliciti pharmatimes
    November 08, 2018
    US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received
  • Bristol-Myers, AbbVie net FDA 'breakthrough' for myeloma drug Empliciti fiercepharma
    August 27, 2018
    The myeloma drug Empliciti is currently approved alongside Revlimid and dexamethasone for patients who have already received anywhere from one to three prior treatments.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service